- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375656
The Effect on Metabolism, Food Intake and Preferences of a Knockout Gene Variant Involved in Carbohydrate Metabolism
Around 10% has type 2 diabetes in Greenland, despite being a practically unknown disease only six decades ago. The drastic increase is of great concern, especially considering the transition that have occurred during the same decades going from a fisher-hunter lifestyle towards a more western lifestyle. Today, traditional marine foods are still increasingly being replaced by imported foods high in refined sugar (sucrose) and starch. Furthermore, recent studies discovered that the Greenlandic population harbors a different genetic architecture behind type 2 diabetes. Hence, obtaining more knowledge on interactions between lifestyle, genetics, and metabolism is therefore crucial in order to ameliorate the growing curve, or maybe even turn it around.
Sucrose intolerance is in general rare; however, it is a common condition in Greenland and other Inuit populations. Here it is caused by a genetic variant in the sucrase-isomaltase (SI) gene, resulting in complete loss of enzyme function and hence an inability to digest sucrose and some of the glycosidic bonds in starch, both carbohydrates that are not part of the traditional Inuit diet. A recent, unpublished study found the variant to be associated with lower BMI, body fat percentage, bodyweight, and lipid levels independent of the lower intake of refined sugar. This might be explained by differences in the metabolism of carbohydrates and in the gut microbiota. The healthier phenotype was confirmed by a SI knockout mouse model, which furthermore interestingly indicated that the variant might alter food and taste preferences.
It is anticipated that the drastic increase in type 2 diabetes in Greenland can be explained at least partly by the complex interaction between lifestyle and genetics. Therefore, the aim is to investigate if metabolic and microbial differences can explain the healthier phenotype of the homozygous carriers of the SI variant than wildtype individuals amd perform a 3-day cross-over dietary intervention using assigning subjects to a traditional Greenlandic diet and a Western diet. Moreover, the aim is to assess whether their food and taste preferences are different. The study will help us to understand the complex interactions between lifestyle, behavior, genetics, the microbiota and the host metabolism.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this human study, effects of the SI knockout variant on metabolism, dietary habits and food preferences will be quantified. The study will be unique by being the first assessing the effect of a complete loss of SI function, which it is only feasible in Arctic populations.
Differences between homozygous (HO) carriers and heterozygous (HE)/wildtype (WT) individuals are suspected to be large on a carbohydrate-rich diet and small on a traditional diet. The following hypotheses will be addressed:
HO carriers metabolize carbohydrates differently than HE+WT individuals:
- HO have a lower glycemic variability on their habitual diet than WT+HE.
- HO have a lower glycemic variability on a starch and sucrose rich diet than WT+HE.
HO have a glycemic variability similar to WT+HE on a traditional diet low in carbohydrates.
HO carriers have different food preferences than HE+WT individuals:
- HO have a lower sweet taste preference compared to WT+HE.
- HO perceive iso-intense solutions of sucrose, fructose, and glucose differently in sweet taste intensity and WT+HE will perceive them iso-intense.
- HO consume less high-sugar-low-fat foods than WT+HE.
HO have similar intake and preference for high-sugar-high-fat foods as WT+HE.
HO carriers have a microbiota different from HE+WT individuals:
- Diversity and abundance of starch-fermenting bacteria is higher in HO than in WT+HE and the abundance of Parabacteroides is lower.
- The increase in starch-fermenting bacteria as well as fecal and circulating levels of short chain fatty acids is larger for HO than in WT+HE on a starch and sucrose rich diet.
- A diet low in carbohydrates will alter the microbiota similarly for HO and WT+HE.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Maniitsoq, Greenland
- Maniitsoq Healthcare Center
-
Nuussuaq, Greenland, 3905
- Pikialaarfik, Greenland Institute of Natural Resources
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Homozygous carriers of the c.273_274delAG variant in the SI-gene (cases)
- Homozygous non-carriers of the c.273_274delAG variant in the SI-gene (controls)
Exclusion Criteria:
- Diagnosis of diabetes or pharmacological treatment of diabetes.
- Gastrointestinal diseases such as inflammatory bowel disease, gastrointestinal cancer, and ulcer. Persons with mild gastrointestinal problems are not excluded, e.g. persons with lactose-intolerance who normally do not have any gastrointestinal problems.
- Homozygous carriers of the TBC1D4 risk variant p.Arg684Ter.
- Lack of compliance with the procedures in the study protocol, judged by Investigator.
- For the homozygous carriers of the c.273_274delAG variant: rise in blood glucose in an oral sucrose tolerance test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Traditional Inuit Diet
The traditional Inuit diet will consist of local foods, being primarily of animal origin, e.g. fish, marine mammals, caribou, and lamb. The diet will be supplemented with eggs, potatoes, and berries, and/or other foods low in starch and with no sucrose content. The diet will therefore have a high content of fat and protein, a low content of carbohydrate and no content of sucrose. The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets. |
Traditional Inuit Diet and Western Diet.
|
|
Experimental: Western Carbohydrate-Rich Diet
The Western diet will have high amounts of grain products, e.g. bread, pasta, rice, as well as fruits and vegetables and some foods with a high sucrose content, e.g. cake and sweet snacks and/or drinks, and cereal products with added sucrose. The diet will have a low amount of meat. Hence, the diet will be high in carbohydrates, starch, and some sucrose and have a lower content of protein and fat. The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets. |
Traditional Inuit Diet and Western Diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic variability during Western diet
Time Frame: During the 3 days of intervention with Western diet.
|
Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between.
|
During the 3 days of intervention with Western diet.
|
|
Glycemic variability during Inuit diet
Time Frame: During the 3 days of intervention with Inuit diet.
|
Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between.
|
During the 3 days of intervention with Inuit diet.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sweet Bias Score
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for foods with sweet relative to savory taste will be assessed using the Leeds Food Preference Questionnaire.
A sweet bias score will be estimated, where a positive score indicates higher preference for sweet relative to savoury foods and a negative score indicates higher preference for savoury foods.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Fat Bias Score
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for foods with high-fat relative to low-fat content will be assessed using the Leeds Food Preference Questionnaire.
A fat bias score will be estimated, where a positive score indicates higher preference for high-fat relative to low-fat foods and a negative score indicates higher preference for low-fat foods.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
High-fat savory preference
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for high-fat savory foods will be assessed in the Leeds Food Preference Questionnaire.
The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Low-fat savory preference
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for low-fat savory foods will be assessed in the Leeds Food Preference Questionnaire.
The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
High-fat sweet preference
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for high-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire.
The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Low-fat sweet preference
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, explicit liking for low-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire.
The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Implicit wanting score: High-fat savory foods
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, implicit wanting for high-fat savory foods will be assessed using the Leeds Food Preference Questionnaire. The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Implicit wanting score: Low-fat savory foods
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, implicit wanting for low-fat savory foods will be assessed using the Leeds Food Preference Questionnaire. The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Implicit wanting score: High-fat sweet foods
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, implicit wanting for high-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire. The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Implicit wanting score: Low-fat sweet foods
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
As a food reward measure, implicit wanting for low-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire. The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category. |
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Habitual diet
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
Habitual dietary intake will be assessed using a food frequency questionnaire.
Macronutrient composition and content of sugar will be assessed as well as characterization of differences in food choice with respect to sweet foods and foods rich in starch.
Intake will be expressed in g/day as well as E%.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Intake in a snacking test meal
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
Using an ad libitum snacking test meal, preferences will be assessed for sweet-taste and content of sucrose and fat as well as other sweeteners than sucrose, e.g.
honey.
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Sucrose sweetness sensitivity
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
Ability to taste a difference between iso-intense solutions of sucrose and fructose+glucose using a 2-alternative forced choice test
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Sweet liking
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
Hedonic rating of liking of iso-intense solutions of sucrose, fructose, glucose and fructose+glucose using a visual analogue scale (0-100 mm)
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Perceived intensity of sugars
Time Frame: Baseline (to assess differences between genotypes, independent of the intervention)
|
Hedonic rating of perceived intensity of iso-intense solutions of sucrose, fructose, glucose and fructose+glucos using a visual analogue scale (0-100 mm)
|
Baseline (to assess differences between genotypes, independent of the intervention)
|
|
Plasma lipids
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in fasting plasma measures of VLDL-cholesterol, LDL-cholesterol, HDL-cholesterol, total cholesterol, remnant cholesterol, and triglycerides
|
The day before and the day after each dietary intervention period.
|
|
Serum insulin
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in serum insulin.
Fasting sample.
|
The day before and the day after each dietary intervention period.
|
|
Plasma CRP
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in plasma CRP.
Fasting sample.
|
The day before and the day after each dietary intervention period.
|
|
Plasma acetate
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in plasma acetate.
Fasting sample.
|
The day before and the day after each dietary intervention period.
|
|
Plasma propionate
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in plasma propionate.
Fasting sample.
|
The day before and the day after each dietary intervention period.
|
|
Plasma butyrate
Time Frame: The day before and the day after each dietary intervention period.
|
Changes in plasma butyrate.
Fasting sample.
|
The day before and the day after each dietary intervention period.
|
|
HbA1c
Time Frame: Baseline
|
Fasting glycated hemoglobin
|
Baseline
|
|
Fecal acetate
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
Changes in fecal acetate.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Fecal propionate
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
Changes in fecal propionate.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Fecal butyrate
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
Changes in fecal butyrate.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Fecal pH
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
pH of fecal samples.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Changes in gut microbiota composition
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
Changes in gut microbiota composition between baseline and end of each dietary intervention period.
Microbiota composition is measured by genome sequencing fecal samples.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Baseline gut microbiota composition
Time Frame: Before intervention (baseline).
|
Characterization of the gut microbiota composition.
Microbiota composition is measured by genome sequencing fecal samples.
|
Before intervention (baseline).
|
|
Fecal carbohydrates
Time Frame: Before and on the last day or on the day after each dietary intervention period.
|
Content of carbohydrates in fecal samples and changes in this during the intervention periods.
|
Before and on the last day or on the day after each dietary intervention period.
|
|
Glycemic variability during habitual diet
Time Frame: Measured during 7 days of wash-out
|
Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE)
|
Measured during 7 days of wash-out
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: Baseline (participant characteristics)
|
Weight (kg).
Measured when the participant is wearing light underwear.
|
Baseline (participant characteristics)
|
|
Height
Time Frame: Baseline (participant characteristics)
|
Height (cm).
Measured when the participant is not wearing shoes.
|
Baseline (participant characteristics)
|
|
Hip circumference
Time Frame: Baseline (participant characteristics)
|
Hip circumference (cm).
Measured when the participant is wearing light underwear.
|
Baseline (participant characteristics)
|
|
Waist circumference
Time Frame: Baseline (participant characteristics)
|
Waist circumference (cm).
Measured when the participant is wearing light underwear.
|
Baseline (participant characteristics)
|
|
Body composition
Time Frame: Baseline (participant characteristics)
|
Body fat percentage measured using a Tanita body composition analyser.
|
Baseline (participant characteristics)
|
|
Plasma lipodomics.
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
|
Plasma metabolomics.
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
|
Plasma proteomics.
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
|
Fecal lipodomics
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
|
Fecal metabolomics.
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
|
Fecal proteomics.
Time Frame: The day before and the day after each dietary intervention period.
|
For future analyses
|
The day before and the day after each dietary intervention period.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marit E Jørgensen, Prof., Steno Diabetes Center Greenland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F15319-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsNot yet recruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on Cross-over study
-
University of CopenhagenNovo Nordisk A/S; Steno Diabetes Center CopenhagenCompleted
-
Centre Hospitalier Universitaire DijonCompletedHeart Failure With Preserved Ejection Fraction | Atrial Dyssynchrony Syndrome | Left Atrio-ventricular AsynchronyFrance
-
Dynasplint Systems, Inc.Completed
-
Inogen Inc.CompletedCognitionUnited States
-
Koya Medical, Inc.CompletedLymphedema | Venous Insufficiency | Chronic Venous Insufficiency | Lymphedema, Lower Limb | Lymphedema of LegUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Singapore National Eye CentreSingHealth Translational Immunology and Inflammation Centre; TTSH Eye ClinicCompletedDry Eye Syndrome | AutoimmunitySingapore
-
Singapore National Eye CentreSingapore General HospitalCompletedDry Eye | GVHDSingapore
-
Istanbul University - Cerrahpasa (IUC)CompletedFall | Vertebral Fracture | Postmenopausal Osteoporosis | Fracture of VertebraTurkey
-
Clinica Universidad de Navarra, Universidad de...University of Copenhagen; University of Leeds; University of Liverpool; University... and other collaboratorsCompletedGlycemic Index | Overweight and ObesityUnited Kingdom, Spain, Denmark